Cladribine for pulmonary Langerhans cell histiocytosis: first prospective evidence and a new therapeutic horizon
European Respiratory Journal · 2026-05 · 67 (5) · 2600040
DOI: 10.1183/13993003.00040-2026 ↗Kurz gefasst
Editorial in der Zeitschrift European Respiratory Journal, online erschienen am 21.05.2026. Verfasst von Sergio Harari und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy sergio@sergioharari.it. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy sergio@sergioharari.it.
- Division of Pulmonary and Respiratory Intermediate Care Unit, MultiMedica IRCCS, Milan, Italy.
- Division of Pulmonary and Critical Care Medicine, Departments of Medicine, Physiology and Biomedical Engineering, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
ORCID-Profile: Sergio Harari, Robert Vassallo
Zitieren
APA
Harari, S., & Vassallo, R. (2026). Cladribine for pulmonary Langerhans cell histiocytosis: first prospective evidence and a new therapeutic horizon. European Respiratory Journal, 67(5), 2600040. https://doi.org/10.1183/13993003.00040-2026
Vancouver
Harari S, Vassallo R. Cladribine for pulmonary Langerhans cell histiocytosis: first prospective evidence and a new therapeutic horizon. European Respiratory Journal. 2026;67(5):2600040. doi:10.1183/13993003.00040-2026
BibTeX
@article{Harari2026,
author = {Harari, Sergio and Vassallo, Robert},
title = {Cladribine for pulmonary Langerhans cell histiocytosis: first prospective evidence and a new therapeutic horizon},
journal = {European Respiratory Journal},
year = {2026},
volume = {67},
number = {5},
pages = {2600040},
doi = {10.1183/13993003.00040-2026}
}
EUVIMED